API
< Back to situations

[ORGANIZATION]

Aiom

Featured in 12 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [IT] [GR]

FDA and EMA approval progress for Rasonque pancreatic cancer

49 clusters · 334 sources · last updated

Latest: Daraxonrasib drug shows promise in treating metastatic pancreatic cancer

On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed as Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDAC). Developed by R

[ACTIVE] [HEALTH] [DE] [CZ] [ES]

Pancreatic cancer awareness and treatment developments

2 clusters · 36 sources · last updated

Latest: European Commission authorizes daraxonrasib for metastatic pancreatic cancer

Medical awareness efforts have focused on pancreatic cancer through initiatives such as the “All Together We Can” campaign by PanCAN. This campaign seeks to raise 250 million US dollars over five years to support researc

[ACTIVE] [HEALTH] [IT]

Italian Association of Medical Oncology advocacy

4 clusters · 40 sources · last updated

Latest: AIOM reports low awareness of precision oncology in breast cancer patients

The Italian Association of Medical Oncology (Aiom) has addressed two primary areas of concern regarding cancer care and prevention. First, the organization called for healthcare budgets that are commensurate with patient

[ACTIVE] [HEALTH] [IT]

Italian health advocacy for smoking restrictions

2 clusters · 15 sources · last updated

Latest: Italian medical associations call for expanded smoking bans

Medical and cancer research organizations, including AIOM, Fondazione AIRC, and Fondazione Umberto Veronesi, have issued a manifesto in Rome to protect non-smokers and younger generations. The document calls for the Ital

[QUIET] [HEALTH] [IT]

AIFA pharmaceutical innovation and access challenges

3 clusters · 27 sources · last updated

Latest: Aiom and Aifa call for equitable access to innovative oncology drugs

The Italian Medicines Agency (AIFA) has initiated institutional dialogues focused on the value of pharmaceutical innovation and its impact on the Italian National Health Service. During a conference in Genoa, discussions

Also covered in